CDK4 and breast cancer: Indeed, in BC cell lines with acquired resistance to CDK4/6i, the combination of MEK inhibitors with CDK4/6i plus ET was shown to be effective in blocking cell proliferation [162,163], supporting a possible role of the MAPK pathway in CDK4/6i acquired resistance.